Literature DB >> 10501205

Neuronal nicotinic receptors in dementia with Lewy bodies and schizophrenia: alpha-bungarotoxin and nicotine binding in the thalamus.

J Court1, D Spurden, S Lloyd, I McKeith, C Ballard, N Cairns, R Kerwin, R Perry, E Perry.   

Abstract

Neuronal nicotinic receptors have been implicated in schizophrenia on the basis of the high incidence of tobacco smoking in patients, abnormalities in cytisine and alpha-bungarotoxin (alphaBGT) binding in the hippocampus, and linkage between auditory P50 deficits and the region of chromosome 15 coding the alpha7 subunit. In another disease associated with psychosis, dementia with Lewy bodies (DLB), in which visual hallucinations predominate, reductions in nicotine binding have been identified in various cortical and subcortical regions. We investigated both alphaBGT and nicotine binding autoradiographically in different thalamic nuclei in autopsy brain tissue from patients with schizophrenia and DLB. AlphaBGT binding in the reticular nucleus was moderately reduced (25%) in schizophrenia and more extensively reduced (50%) in DLB. There were no significant alterations in nicotine binding in schizophrenia, and in DLB, a trend towards moderate reductions in most nuclei reached significance in the lateral dorsal nucleus. It is concluded that widespread abnormalities of thalamic nicotine are not implicated in schizophrenia or DLB, but that reticular alphaBGT binding may be involved to a lesser and greater extent in the pathophysiology or psychopathology of both disorders.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10501205     DOI: 10.1046/j.1471-4159.1999.0731590.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  71 in total

Review 1.  The genetics of sensory gating deficits in schizophrenia.

Authors:  Robert Freedman; Ann Olincy; Randall G Ross; Merilyne C Waldo; Karen E Stevens; Lawrence E Adler; Sherry Leonard
Journal:  Curr Psychiatry Rep       Date:  2003-06       Impact factor: 5.285

Review 2.  Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.

Authors:  Carrie K Jones; Nellie Byun; Michael Bubser
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

3.  Transcriptional repression of the α7 nicotinic acetylcholine receptor subunit gene (CHRNA7) by activating protein-2α (AP-2α).

Authors:  Jessica Finlay-Schultz; Andrew Canastar; Margaret Short; Mohamed El Gazzar; Christina Coughlan; Sherry Leonard
Journal:  J Biol Chem       Date:  2011-10-06       Impact factor: 5.157

4.  Distinct neural generators of sensory gating in schizophrenia.

Authors:  Terrance J Williams; Keith H Nuechterlein; Kenneth L Subotnik; Cindy M Yee
Journal:  Psychophysiology       Date:  2010-08-23       Impact factor: 4.016

Review 5.  Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits.

Authors:  Manoranjan S D'Souza; Athina Markou
Journal:  Neuropharmacology       Date:  2011-02-01       Impact factor: 5.250

6.  Increased Thalamocortical Connectivity in Schizophrenia Correlates With Sleep Spindle Deficits: Evidence for a Common Pathophysiology.

Authors:  Bengi Baran; Fikret Işık Karahanoğlu; Dimitrios Mylonas; Charmaine Demanuele; Mark Vangel; Robert Stickgold; Alan Anticevic; Dara S Manoach
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2019-05-08

7.  Spatial and intracellular relationships between the alpha7 nicotinic acetylcholine receptor and the vesicular acetylcholine transporter in the prefrontal cortex of rat and mouse.

Authors:  A M Duffy; P Zhou; T A Milner; V M Pickel
Journal:  Neuroscience       Date:  2009-04-15       Impact factor: 3.590

Review 8.  Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.

Authors:  Ann Olincy; Karen E Stevens
Journal:  Biochem Pharmacol       Date:  2007-07-17       Impact factor: 5.858

9.  Initial phase 2 trial of a nicotinic agonist in schizophrenia.

Authors:  Robert Freedman; Ann Olincy; Robert W Buchanan; Josette G Harris; James M Gold; Lynn Johnson; Diana Allensworth; Alejandrina Guzman-Bonilla; Bettye Clement; M Patricia Ball; Jay Kutnick; Vicki Pender; Laura F Martin; Karen E Stevens; Brandie D Wagner; Gary O Zerbe; Ferenc Soti; William R Kem
Journal:  Am J Psychiatry       Date:  2008-04-01       Impact factor: 18.112

Review 10.  Nicotine and nicotinic system in hypoglutamatergic models of schizophrenia.

Authors:  Yousef Tizabi
Journal:  Neurotox Res       Date:  2007-12       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.